Abstract: The present invention relates to a pharmaceutical composition containing a collagen-binding dimeric fusion protein comprising an extracellular domain of glycoprotein VI, the fusion protein having an amino acid sequence of SEQ ID NO: 1, or an amino acid sequence that is at least 99% homologous to the amino acid sequence of SEQ ID NO: 1 for use in the prevention or treatment of thrombotic complications in a patient suffering from an acute cardiovascular event, and fulfilling at least one of the following criteria (i) to (v): (i) a degree of carotid stenosis of at least 50% as defined by NASCET criteria or at least 70% as defined by ECST; (ii) no anti-platelet therapy prior to the acute cardiovascular event, (iii) revascularization procedures selected from carotid endarterectomy (CEA) or carotid angioplasty and stenting (CAS) and thrombolysis and thrombectomy via stent retriever are indicated; (iv) revascularization procedures selected from coronary angioplasty and stenting, and coronary artery bypass grafting (

Abstract: The present invention relates to peptides, their use in the treatment, amelioration or prevention of chronically active autoimmune inflammation, in particular rheumatoid arthritis, and to pharmaceutical compositions comprising the same.

Abstract: A pharmaceutical composition for parenteral application. comprising (a) more than 2.4 mg/ml of a collagen-binding dimeric fusion protein comprising an extracellular domain of glycoprotein VI, the fusion protein having an amino acid sequence of SEQ ID NO: 1, or an amino acid sequence that is at least 99% homologous to the amino acid sequence of SEQ ID NO: 1; and (b) a pharmaceutically acceptable buffer, the buffer comprising (b1) a buffering component in combination with a ph adjusting agent, which is 10 mM His/HCl, and (b2) 4 percent by weight of mannitol and (b3) 2.

Abstract: An isolated nucleic acid molecule selected from the group consisting of: vi. a nucleic acid molecule comprising a nucleotide sequence which is at least 85% identical to the nucleotide sequence of SEQ ID NO:1 or a complement thereof; vii. a nucleic acid molecule comprising a fragment of at least 1500 consecutive nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof; viii. a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least 85% identical to SEQ ID NO:2; ix. a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 500 contiguous amino acids of SEQ ID NO: 2; and x.

Abstract: The present invention provides anti-thrombotic agents, methods for screening for said anti-thrombotics agents and methods of treating thrombotic and other cardiovascular disorders.

Abstract: The present invention provides anti-thrombotic agents, methods for screening for said anti-thrombotics agents and methods of treating thrombotic and other cardiovascular disorders.

Abstract: The present disclosure relates to agents which interfere with the binding of GPVI to various components. Agents which interfere with GPVI interaction with one or both of fibronectin and vitronectin or sequences thereof are also disclosed. Methods of treating disorders or diseases which involve pathological, dysfunctional or non-pathological interaction of GPVI with fibronectin and/or vitronectin are included in the present disclosure. The invention also relates to uses of agents for the prevention or treatment of disorders arising from blood platelet adhesion and aggregation.

Abstract: The present invention provides a fusion protein comprising (1) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of the immunoglobulin or a function-conservative part thereof, characterized by a polypeptide chain having an amino acid sequence as shown in FIG. 7 and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.

Abstract: The present invention provides a fusion protein comprising (a) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of an immunoglobulin or a function-conservative part thereof, characterised by a polypeptide chain having an amino acid sequence as shown in FIG. 7 and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.

Abstract: The present invention provides anti-thrombotic agents, methods for screening for said anti-thrombotics agents and methods of treating thrombotic and other cardiovascular disorders.

Abstract: A 5H-Thiazolo[3,2]pyrimidine derivative or a salt thereof for use as a medicine, which is represented by the following formula (A): wherein R represents an optionally substituted phenyl or pyridyl group; R4 represents a hydroxyl group, an amino group, a straight chain or branched alkoxy group, a straight chain or branched alkyl group, a cycloalkyloxy group, an alkylamino group, a cycloalkylamino group, a dialkylamino group, R5 represents a hydrogen atom, a straight chain or branched alkyl group, R6 and R7, which may be the same or different represent a hydrogen atom, a halogen atom, a straight chain or branched alkyl group, a straight chain or branched alkoxy group, a straight chain or branched alkenyl group, a cycloalkyl group, an aryl group, X, Y, and Z which may be same or different represent a hydrogen atom, a halogen atom, a carboxyl group a nitro group, a cyano group, an alkyl group, an alkoxy group or an acyl group.

Abstract: The invention discloses use of peptide containing an essential ventricular myosin light chain type 1 (vMLC1) amino acid sequence, which is functional as cleavage site for caspase-3, in the screening for a compound for the treatment of chronic or acute cardiovascular disease. Further, screening methods for inhibitors of the caspase-3-mediated cleavage of vMLC1 are disclosed.

Abstract: The present invention provides a fusion protein comprising (1) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of the immunoglobulin or a function-conservative part thereof, characterised by a polypeptide chain having an amino acid sequence as shown in FIG. 7 and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.

Abstract: The present invention provides a fusion protein comprising (a) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of an immunoglobulin or a function-conservative part thereof, characterised by a polypeptide chain having an amino acid sequence as shown in FIG. 7 and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.

Abstract: A method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle i by administering an agent capable of binding to a phosducin binding site of G&bgr;&ggr; is provided. Said phosducin binding site is preferably a binding site of N-terminal truncated phosducin. Further, methods of identifying compounds capable of increasing the contractility of a heart muscle and methods of identifying compounds capable of inhibiting G&bgr;&ggr;-mediated processes are provided.